Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine

European Journal of Pediatrics

Volumn 155, Issue 5, 1996, Pages 368-372

  De Sanctis, V ^a   Pinamonti, A ^a   Di Palma, A ^a   Sprocati, M ^a   Atti, G ^a   Gamberini, M R ^a   Vullo, C ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Bone lesions; Desferrioxamine; Development; Growth; Thalassaemia major

Indexed keywords

DEFEROXAMINE; FERRITIN;

ADOLESCENT; ARTICLE; BONE LESION; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; FEMALE; FEMUR HEAD EPIPHYSIOLYSIS; GROWTH RETARDATION; HUMAN; MALE; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RICKETS; SHORT STATURE; THALASSEMIA MAJOR; VALGUS KNEE;

EID: 0029963993     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01955263     Document Type: Article

References (20)

1. Arden GB, Wonke B, Kennedy C, Huehns ER (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophtalmol 68:873-877
2. Brill PW, Winchester P, Giardina PI, Cunnigham-Rundles S (1991) Desferrioxamine induced bone dysplasia in patients with thalassaemia major. A J R 156:561-565
3. Cohen A, Martin M, Schwartz E (1984) Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 58:369-373
4. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER (1984) Ocular toxicity of high dose intravenous desferrioxamine. Lancet II: 181-184
5. De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B (1994) Effect of different treatment regimes on linear growth and final height in β-thalassaemia major. Clin Endocrinol 40: 791-798
6. De Virgilis S, Argiolu F, Sanna G, Cornacchia G, Cossu P, Cao A, Mallardi V, Puxeddu P (1979) Auditory involvement in thalassaemia major. Acta Haematol 61:209-213
7. De Virgilis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M, Pirastu GF, Cao A (1988) Desferrioxamine-induced growth retardation in patients with thalassemia major. J Pediatr 113: 661-669
8. Elena MG, Fedele A, Gianino P, Giordanino S, Murru P, Tosi C, Vanelli S (1992) Velocità di crescita del bambini talassemici sottoposti a diversi protocolli di terapia chelante. Min Pediatr 44:41-42
9. Fosburg MT, Nathan DG (1990) Treatment of Cooley's anemia. Blood 76: 435-444
10. Lankhanpal V, Schocket SS, Jiji R (1986) Desferrioxamine induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 91:443-451
11. Llados I, Vallory EA, Girot R, Lenoir G, Payet M, Houze P, Bourden R (1989) Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children. Eur J Pediatr 148:503-506
12. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Looan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman M (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusion. N Engl J Med 314:869-873
13. Olivieri NF, Koren G, Harris J, Khattak S, Freedman M, Templeton DM, Bailey JD, Reilly BJ (1992) Growth failure and bony changes induced by desferoxamine. Am J Pediatr Hematol/Oncol 14(1):48-56
14. Olivieri NF, Nathan DG, Mac Millan JH, Wayne AS, Liu PP, Mc Gee A, Martin M, Koren G, Cohen AR (1994) Survival in medically treated patients with homozygous β-thalassaemia. N Eng J Med 331:574-578
15. Porter JB, Jaswon MS, Huhens ER, East CA, Jonathan WP (1989) Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol 73:403-109
16. Rebulla P, Modell B (1991) Transfusion requirements and effects in patients with thalassaemia major. Lancet 337:277-280
17. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C (1979) Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42:547-555
18. Tanner JM (1978) Physical growth and development. In: Forfar JD, Arneil GC (eds) Textbook of paediatrics. Second edition. Livingston, Edinburgh, pp 287-290
19. Weatherall DJ, Clegg JG (1981) The thalassaemia syndromes. Third edition. Blackwell Scientific Publication, Oxford
20. Wolfe L, Olivieri N, Sallan D, Olan S, Rose W, Propper R, Freedman M, Nathan D (1985) Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. N Engl J Med 312:1600-1603